# Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

> **NCT05234190** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Quell Therapeutics Limited** · enrollment: 33 (estimated)

## Conditions studied

- Rejection; Transplant, Liver
- Liver Failure
- Liver Diseases

## Interventions

- **DRUG:** QEL-001

## Key facts

- **NCT ID:** NCT05234190
- **Lead sponsor:** Quell Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-21
- **Primary completion:** 2026-02
- **Final completion:** 2040-09
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234190, "Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05234190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*